News

Xeno Diagnostics expands facility

We are excited to announce the expansion of the Xeno Diagnostics facility in Indianapolis, IN. The additional 2700 square feet of office and laboratory space will allow the expansion of our immuno-oncology program.

Dendritic Cell (APC) and Autologous T-Cell Response (White Paper)

Xeno Diagnostics has added a mixed lymphocyte tumor cell assay to our list of services. The mixed lymphocyte tumor cell (MLTuC) is a method for generating T-lymphocytes that are cytotoxic to specific tumor cells. This assay offers a means to screen various pharmacological agents for their ability to enhance T-cell cytotoxicity to specific neoplasms. Click here to download.

Cells Isolated from Cadaveric Bone Marrow are Safe for Use in Bone Healing and Effective at Promoting Osteogenic Re-construction

The efficacy and immune-modulation of mesenchymal stem cells is well documented. The issue of obtaining mesenchymal stem cells without patient risk, extensive intra-operative procedure, cell manipulation or exposure of cells to harmful reagents remains an issue. This study was designed to test the viability, composition, and osteogenic potential of cells derived…read more.

Xeno has won its 4th consecutive Laboratory Excellence Award following its most recent regulatory inspection.

Xeno Diagnostics has received an award for Laboratory Excellence following its most recent COLA inspection, making this the fourth consecutive inspection for Xeno to receive this award. Xeno has met all criteria for Laboratory Accreditation by COLA, a national healthcare accreditation organization. Accreditation is earned only by laboratories that apply rigid standards of quality in day-to-day operations, demonstrate continued accuracy in the performance of proficiency testing, and pass a rigorous on-site laboratory survey with no citations…. read more

Modfied glycan models of pig-to-human xenotransplantation do not enhance the human-anti-pig T cell response.

Genetically modified porcine models of pig-to-human xenotransplantation offer the most immediate answer to a growing shortage of available solid organs. Recently a modified porcine glycan model has been discovered that reduces human antibody binding to levels comparable with allograft standards. As this background provides an answer to the problem of acute humoral xenograft rejection (AHXR), it is important to consider the impact these modifications have on…read more

Xeno Diagnostics Receives 3rd Award for Laboratory Excellence

Xeno Diagnostics has again received an award for Laboratory Excellence following its most recent COLA inspection. Xeno has met all criteria for Laboratory Accreditation by COLA, a national healthcare accreditation organization. Accreditation is earned only by laboratories that apply rigid standards of quality in day-to-day operations, demonstrate continued accuracy in the performance of proficiency testing, and pass a rigorous on-site laboratory survey.

Xeno Diagnostics Adds Dr. Daniel Wierda as Director of Research and Development

Xeno Diagnostics, LLC, announced today that Dr. Daniel Wierda has joined Xeno as their new Director of Research and Development. Dan brings with him a great depth of experience in the area of immunotoxicology and cell-based assays. Prior to joining Xeno, Dan worked for 22 years at Eli Lilly and Company as a research scientist and toxicologist…read more

Xeno Diagnostics, LLC Receives Award for Laboratory Excellence

Xeno Diagnostics, LLC has met all criteria for Laboratory Accreditation by COLA, a national healthcare accreditation organization. Accreditation is given only to laboratories that apply rigid standards of quality in day-to-day operations, demonstrate continued accuracy in the performance of proficiency testing, and pass a rigorous on-site laboratory survey…read more